⌕
Lakefront Biotherapeutics · LKFT · Nasdaq
Tenet 82 · Strong
Compare
$34.39−1.15%At closeTenet 82 · Strong
$34.39−0.40 (−1.15%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Lakefront Biotherapeutics (LKFT) Stock

Lakefront Biotherapeutics (LKFT) closed at $34.39 on Nov 17, 2026; its Tenet Score is 82 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

13 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$34.39
Nov 17, 2026
Market cap
$2.3B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
6.1×
fiscal year to Dec 31, 2025 · as of close, Nov 16, 2026
52-week range
25.68 – 36.24
low → high · as of close, Nov 16, 2026
Tenet Score
82/100
Strong · 340 Healthcare peers

Industry: Drugs

Lakefront Biotherapeutics NV scores 82/100. Strong. Strongest on quality and financial health, trading at 6× earnings versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
82/ 100
Strong
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
87
Quality
92
Health
89
Growth
60

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueBQualityAHealthBGrowthCMomentumD
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
3.9×
fiscal year to Dec 31, 2025 · as of close, Nov 16, 2026
P/S
1.8×
price to sales, fiscal 2025 · as of close, Nov 16, 2026
ROE
100%
fiscal year to Dec 31, 2025
Operating margin
26.5%
before interest and tax
Net margin
28.9%
fiscal year to Dec 31, 2025
Current ratio
40.29
fiscal year to Dec 31, 2025
Net debt / EBITDA
—
Not reported in the company's filings for this period.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Lakefront Biotherapeutics NV

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of cli…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 5 US ETFs · top wrappers by weightSee all ETFs holding LKFT →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Lakefront Biotherapeutics in?

Lakefront Biotherapeutics is in the Healthcare sector and the Drugs industry.

What is Lakefront Biotherapeutics' Tenet Score?

Lakefront Biotherapeutics' Tenet Score is 82 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.